Oct 31, 2018
In Multiple Myeloma, Janssen's Darzalex Posted Significant Gains Over the Past Six Months, but May Face an Increasingly Restrictive Payer Environment
Aug 27, 2018
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
May 16, 2018
Janssen to Present New Data in Urothelial, Hematologic and Prostate Cancers at ASCO 2018, Including Best of ASCO Selections
Mar 14, 2018
Hillstream to Present at 2018 China Healthcare Investing & Partnering Symposium
Jan 17, 2018
FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label
Dec 21, 2017
Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
Dec 12, 2017
Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple
Dec 11, 2017
PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting
Dec 11, 2017
New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
Dec 05, 2017
SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler(TM) with SKY92 in Multiple Myeloma
Aug 30, 2017
Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma
Aug 30, 2017
FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS® (Carfilzomib) Label
Aug 23, 2017
Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology
Aug 09, 2017
PharmaMar Starts a Quadruple Combination Study With Aplidin® for the Treatment of Multiple Myeloma
Jul 25, 2017
Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
Jun 20, 2017
Data Presentations at European Hematology Association (EHA) 22nd Annual Congress Further Validate SkylineDx Prognostic Tools in Multiple Myeloma